Home › NDC Lookup › RxCUI directory › RxCUI 2268221

Ubrogepant 100 MG Oral Tablet — RxCUI 2268221

Name: Ubrogepant 100 MG Oral Tablet (RxCUI 2268221)
Creator: Brian Staiger, PharmD

RxNorm drug concept · Semantic clinical drug

RxCUI 2268221 Semantic clinical drug · SCD ● Current RxNorm concept 2 FDA products 9 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by Dr. Brian Staiger, PharmD

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2268221

Official nameUbrogepant 100 MG Oral Tablet

Concept typeSemantic clinical drug (SCD)

RxNorm statusCurrent RxNorm concept

FDA products mapped2

Package NDCs mapped9

Reported Medicaid activity (SDUD)329,850 prescriptions · 52 state & territory Medicaid programs · latest period Q4 2025

RxNorm release07/06/2026

Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Ubrogepant: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist

It treats a migraine attack in adults once it has started, with or without aura. It is not meant to prevent migraines, so it won't reduce how often you get them.
Swallow the tablet when a migraine starts. You can take it with or without food. If you need it, a second dose can be taken at least 2 hours after the first. Follow the dose your p...
The most common are nausea, sleepiness and dry mouth. Because of the sleepiness, notice how it affects you before doing anything that needs full alertness.
Get help right away for trouble breathing, or swelling of your face or throat, hives or rash, and stop the medicine. Also call if you notice high blood pressure or fingers or toes...

📖 Read our full Ubrogepant guide →

🕸️ Concept Web — How Ubrogepant 100 MG Oral Tablet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.

This page's concept Ubrogepant 100 MG Oral Tablet RxCUI 2268221 Semantic clinical drug · SCD

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

Ingredients 1

The active substance itself — no strength, form, or brand attached yet.
- Ubrogepant 2268216 IN
Brand names 1

The same medicine's trade names. A brand name alone says nothing about strength or form.
- Ubrelvy 2268222 BN
Dose forms 9

The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
- Ubrogepant Oral Tablet 2268220 SCDF
- Ubrogepant Oral Product 2268218 SCDG
- Ubrogepant Pill 2268219 SCDG
- Ubrogepant Oral Tablet [Ubrelvy] 2268224 SBDF
- Ubrelvy Oral Product 2268225 SBDG
- Ubrelvy Pill 2268226 SBDG
- Oral Tablet 317541 DF
- Oral Product 1151131 DFG
- +1 more in this family
Clinical & branded drugs 3

Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
- Ubrogepant 100 MG 2268217 SCDC
- Ubrogepant 100 MG Oral Tablet [Ubrelvy] 2268227 SBD
- Ubrogepant 100 MG [Ubrelvy] 2268223 SBDC

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.

These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Ubrogepant 100 MG SCDC · 2268217
Ubrogepant Oral Tablet SCDF · 2268220
Ubrogepant Oral Product SCDG · 2268218
Ubrogepant Pill SCDG · 2268219

Brand-Name Concepts

Ubrogepant 100 MG Oral Tablet [Ubrelvy] SBD · 2268227
Ubrogepant 100 MG [Ubrelvy] SBDC · 2268223
Ubrogepant Oral Tablet [Ubrelvy] SBDF · 2268224
Ubrelvy Oral Product SBDG · 2268225
Ubrelvy Pill SBDG · 2268226
Ubrelvy BN · 2268222

📦 FDA Products & Package NDCs

2 products · 9 package NDCs

9 package NDCs map to RxCUI 2268221 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.

Package NDC	Package	Brand / generic name	Labeler	Marketing start
00023-6498-01	1 PACKET in 1 BOX (0023-6498-01) / 1 TABLET in 1 PACKET	UBRELVY	Allergan, Inc.	2019-12-23
00023-6498-04	4 PACKET in 1 BOX (0023-6498-04) / 1 TABLET in 1 PACKET	UBRELVY	Allergan, Inc.	2019-12-23
00023-6498-10	10 PACKET in 1 BOX (0023-6498-10) / 1 TABLET in 1 PACKET (0...	UBRELVY	Allergan, Inc.	2019-12-23
00023-6498-16	16 PACKET in 1 BOX (0023-6498-16) / 1 TABLET in 1 PACKET (0...	UBRELVY	Allergan, Inc.	2019-12-23
00023-6498-30	30 PACKET in 1 BOX (0023-6498-30) / 1 TABLET in 1 PACKET (0...	UBRELVY	Allergan, Inc.	2019-12-23
00023-6501-01	1 PACKET in 1 BOX (0023-6501-01) / 1 TABLET in 1 PACKET	UBRELVY	Allergan, Inc.	2019-12-23
00023-6501-10	10 PACKET in 1 BOX (0023-6501-10) / 1 TABLET in 1 PACKET (0...	UBRELVY	Allergan, Inc.	2019-12-23
00023-6501-16	16 PACKET in 1 BOX (0023-6501-16) / 1 TABLET in 1 PACKET (0...	UBRELVY	Allergan, Inc.	2019-12-23
00023-6501-30	30 PACKET in 1 BOX (0023-6501-30) / 1 TABLET in 1 PACKET (0...	UBRELVY	Allergan, Inc.	2019-12-23

Observed labelers: Allergan, Inc. (9) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7

openFDA export observedJul 14, 2026

RxNorm release07/06/2026

Methodology2026-07-full-catalog-v1

A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.